Jimena Cubero Carralero, Presenter: Nothing to Disclose

Susana Gonzalez Cabestreros, Abstract Co-Author: Nothing to Disclose

Rosario Vazquez Carnero, Abstract Co-Author: Nothing to Disclose

Ana Isabel Montero Montero, Abstract Co-Author: Nothing to Disclose

Carmen Ortiz Ibanez, Abstract Co-Author: Nothing to Disclose

Juan Manuel Fernandez Gallardo, Abstract Co-Author: Nothing to Disclose

o The accuracy of breast MRI predicting the presence of residual disease after neoadjuvant chemotherapy depends on breast cancer subtypes, with less sensitivity and specificity in luminal tumors. o There are several causes of inaccurate diagnosis when monitoring with MRI tumors response to neoadjuvant chemotherapy  Overestimation includes: presence of sclerosis, reactive inflammation and ductal carcinoma in situ  Underestimation includes: lack of inflammation or vascularization and fragmentation of the tumor.  

o Brief review of the literature. o Parameters used in contrast-enhanced MRI to monitor response to neoadjuvant chemotherapy. o Illustration with cases of main pitfalls in post-chemotherapy MRI evaluation of luminal tumors with pathologic correlation. o Tips and tricks. o Conclusions.  

http://abstract.rsna.org/uploads/2014/14003166/14003166_qqsj.pdf

Cubero Carralero, J, Gonzalez Cabestreros, S, Vazquez Carnero, R, Montero Montero, A, Ortiz Ibanez, C, Fernandez Gallardo, J, The Mischief-Makers; MRI Diagnosis of Luminal Breast Tumors after Neoadjuvant Chemotherapy with Pathological Correlation.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14003166.html